(2021) demonstrated that NK‐EVs loaded with BCL‐2 siRNAs effectively inhibited the overexpression of BCL‐2 in breast cancer cells, significantly enhancing tumour cell killing. This evidence concerns the gene BCL2 and breast cancer.